Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | RHOA | P61586 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9953568 | 0.89 | PDE10A (0.61) | PDE10AMEN1KMT2ARHOAALDH1A1 | |
| SCHEMBL25412037 | 0.82 | PDE10A (0.60) | PDE10AMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL12066225 | 0.81 | PDE10A (1.00) | PDE10AMEN1KMT2AMAPT | |
| SCHEMBL9042289 | 0.81 | PDE10A (0.59) | PDE10AMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL9043569 | 0.79 | CYP1A2 (0.61) | PDE10AMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL7317271 | 0.78 | PDE10A (0.77) | PDE10AMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL7317281 | 0.78 | PDE10A (0.77) | PDE10AMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL9233026 | 0.77 | KDM4E (0.50) | PDE10AMEN1KMT2ARHOAALDH1A1 | |
| SCHEMBL547194 | 0.77 | FFAR1 (0.63) | KDM4EFFAR1AKR1B1CYP1A2CHRM1 | |
| SCHEMBL28237594 | 0.77 | PDE10A (0.81) | PDE10AMEN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1041928-C | Imidazoloquinoxalinone derivatives as eaa antagonists | BASF AG (DE) | 1999-02-03 | — | — | CN | claimed |
| CN-1120336-A | Imidazoloquinoxalinone derivatives as eaa antagonists | BASF AG (DE) | 1996-04-10 | — | — | CN | claimed |
| EP-3318561-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3318561-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-10562916-B2 | Substituted quinoxalines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562916-B2 | Substituted quinoxalines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-2576540-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-2576540-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-09-04 | — | — | EP | disclosed |
| CN-109562183-A | Liquid preparation for contact lens containing hydrolysis derivatives of hyaluronic acids and cationic system fungicide | 日本欧得士株式会社 | 2019-04-02 | — | — | CN | disclosed |
| EP-3318561-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-3318561-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2018-05-09 | — | — | EP | disclosed |
| US-5908954-A | CHEMICAL INTERMEDIATE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-06-01 | — | — | US | disclosed |
| EP-0901468-A1 | PREPARATION OF LACTAMS FROM ALIPHATIC $g(a),$g(v)-DINITRILES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-03-17 | — | — | EP | disclosed |
| CN-1041928-C | Imidazoloquinoxalinone derivatives as eaa antagonists | BASF AG (DE) | 1999-02-03 | — | — | CN | disclosed |
| US-5858736-A | CONTACTING DINITRILE IN AQUEOUS MIXTURE WITH ENZYME CATALYST HAVING ALIPHATIC NITRILASE ACTIVITY OR COMBINATION OF NITRILE HYDRATASE AND AMIDASE ACTIVITY, CONTACTING PRODUCT WITH HYDROGEN AND HYDROGENATION CATALYST TO PRODUCE LACTAM | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-01-12 | — | — | US | disclosed |
| US-5814508-A | TREATING A WHOLE CELL CATALYST TO SELECT FOR A REGIOSELECTIVE NITRILASE ACTIVITY OR A NITRILE HYDRATASE ACTIVITY; CATALYTIC CONVERSION OF ALPHA-OMEGA DINITRILES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-09-29 | — | — | US | disclosed |
| WO-1997044318-A1 | PREPARATION OF LACTAMS FROM ALIPHATIC α,φ-DINITRILES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-11-27 | — | — | WO | disclosed |
| CN-1120336-A | Imidazoloquinoxalinone derivatives as eaa antagonists | BASF AG (DE) | 1996-04-10 | — | — | CN | disclosed |
| EP-0691970-A1 | IMIDAZOLOQUINOXALINONE DERIVATIVES AS EAA ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 1996-01-17 | — | — | EP | disclosed |
| WO-1994022865-A1 | IMIDAZOLOQUINOXALINONE DERIVATIVES AS EAA ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562916-B2 | Substituted quinoxalines as PDE-10 inhibitors | PDE4A, PDE2A, PDE9A | PDE10A 6/4885MEN1 2701/4885KMT2A 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.